Ligelizumab 120 mg + Ligelizumab 240 mg
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy
Trial Timeline
Apr 27, 2023 → Mar 6, 2025
NCT ID
NCT05678959About Ligelizumab 120 mg + Ligelizumab 240 mg
Ligelizumab 120 mg + Ligelizumab 240 mg is a phase 3 stage product being developed by Novartis for Food Allergy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05678959. Target conditions include Food Allergy.
What happened to similar drugs?
2 of 2 similar drugs in Food Allergy were approved
Approved (2) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05678959 | Phase 3 | Terminated |
Competing Products
17 competing products in Food Allergy